Tumor Microenvironment Characterization Identifies KIF15 as an Immunosuppressive Driver in Breast Cancer
Bo Zhang, Feiran Wang, Huiwei Huang, Xiang Zhong, Qian Chen, Xiancheng Liu
TL;DR
This study identifies KIF15 as a key driver of immunosuppression in breast cancer and introduces a TMEscore to predict prognosis and immunotherapy response.
Contribution
The study introduces TMEscore and identifies KIF15 as a novel immunosuppressive driver in breast cancer.
Findings
Patients with high TMEscore show better survival and response to immunotherapy.
KIF15 knockdown enhances dendritic cell and CD8+ T cell activity in the tumor microenvironment.
TMEscore is an independent prognostic biomarker for breast cancer.
Abstract
The various cellular composition of the tumor microenvironment (TME) comprises the fundamental units of tumor tissue. The types of stromal cells in the TME are genetically stable, with reduced risk of tumor recurrence and drug resistance. More and more evidence shows their clinicopathological significance and therapeutic effect in predicting prognosis. Therefore, we performed an integrated analysis of the breast cancer TME, correlating it with genomic landscapes and clinical profiles. In this work, we first conducted unsupervised hierarchical clustering on 830 tumors in the breast cancer cohort. Then, we defined three TME phenotypes and applied principal component analysis to construct a TMEscore for quantifying TME. Analysis revealed that patients stratified into the high TMEscore cohort exhibited superior survival compared to the low‐scoring group. Additionally, a high TMEscore is…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
Figure 16
Figure 17
Figure 18
Figure 19
Figure 20
Figure 21
Figure 22
Figure 23
Figure 24
Figure 25
Figure 26
Figure 27
Figure 28
Figure 29
Figure 30
Figure 31
Figure 32
Figure 33
Figure 34
Figure 35Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Immunotherapy and Biomarkers · Immunotherapy and Immune Responses · Ferroptosis and cancer prognosis